Rickyt089
2021-12-03
Like pls
Gilead says it expects remdesivir to remain effective against omicron variant<blockquote>吉利德表示预计瑞德西韦对奥密克戎变种仍有效</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":601186804,"tweetId":"601186804","gmtCreate":1638497971519,"gmtModify":1638497971694,"author":{"id":3571612770300673,"idStr":"3571612770300673","authorId":3571612770300673,"authorIdStr":"3571612770300673","name":"Rickyt089","avatar":"https://static.tigerbbs.com/4e75fb09fa53aa8d7db329d6599d40c1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls</p></body></html>","htmlText":"<html><head></head><body><p>Like pls</p></body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/601186804","repostId":1103986245,"repostType":4,"repost":{"id":"1103986245","kind":"news","pubTimestamp":1638497062,"share":"https://www.laohu8.com/m/news/1103986245?lang=zh_CN&edition=full","pubTime":"2021-12-03 10:04","market":"us","language":"en","title":"Gilead says it expects remdesivir to remain effective against omicron variant<blockquote>吉利德表示预计瑞德西韦对奥密克戎变种仍有效</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1103986245","media":"Fox13","summary":"FOSTER CITY, Calif.-Gilead Sciences, the maker of the COVID-19 treatment remdesivir, said it expects","content":"<p><b>FOSTER CITY, Calif.</b>-Gilead Sciences, the maker of the COVID-19 treatment remdesivir, said it expects the drug to remain effective against the new COVID-19 omicron variant and will continue to conduct further laboratory testing to confirm.</p><p><blockquote><b>加利福尼亚州福斯特市。</b>——新冠治疗药物瑞德西韦的制造商吉利德科学表示，预计该药物对新冠奥密克戎变种仍有效，并将继续进行进一步的实验室检测以确认。</blockquote></p><p> Remdesivir, which is sold as Veklury, is an antiviral drug used to treat hospitalized COVID-19 patients 12 and up. It was the first COVID-19 treatment to receive FDA approval and recent data from a Phase 3 clinical trial found it to be 87% effective at reducing hospitalizations in high-risk patients who were diagnosed early.</p><p><blockquote>Remdesivir以Veklury出售，是一种抗病毒药物，用于治疗12岁及以上的住院COVID-19患者。这是第一个获得FDA批准的COVID-19治疗方法，最近一项3期临床试验的数据发现，它在减少早期诊断的高危患者住院方面有87%的有效性。</blockquote></p><p> In a statement,Gilead said Wednesday that it conducted a genetic analysis of more than 200 available sequences of the omicron variant, including those from South Africa, Asia and Europe, and found no additional \"prevalent mutations\" in the omicron variant as compared to previous strains.</p><p><blockquote>吉利德周三在一份声明中表示，它对奥密克戎变种的200多个可用序列进行了基因分析，包括来自南非、亚洲和欧洲的序列，与之前的菌株相比，奥密克戎变种没有发现额外的“流行突变”。</blockquote></p><p> \"This suggests that Veklury (remdesivir) will continue to be active against the Omicron variant and Gilead will conduct laboratory testing to confirm this analysis,\" the biopharmaceutical company said.</p><p><blockquote>这家生物制药公司表示：“这表明Veklury（remdesivir）将继续对奥密克戎病毒变种发挥作用，吉利德将进行实验室测试来证实这一分析。”</blockquote></p><p> The statement comes a day after Regener on said in its own statement that mutations present in the omicron variant \"indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody-conveyed immunity,\" including the company’s cocktail of two monoclonal antibodies.</p><p><blockquote>此前一天，Regener On在自己的声明中表示，奥密克戎变种中存在的突变“表明疫苗诱导和单克隆抗体传递的免疫的中和活性可能会降低”，包括该公司的两种单克隆抗体的混合物。</blockquote></p><p> Much remains unknown about omicron, including how contagious it is and whether it can evade vaccines and various treatments. But as reports of infections linked to the new strain have popped up in more parts of the globe, governments have rushed to impose restrictions in an effort to keep it out.</p><p><blockquote>关于奥密克戎病毒还有很多未知之处，包括它的传染性如何以及它是否可以逃避疫苗和各种治疗。但随着全球更多地区出现与新毒株相关的感染报告，各国政府纷纷采取限制措施，努力将其拒之门外。</blockquote></p><p> South African researchers first alerted the World Health Organization to omicron last week, but it is not known where or when the variant first emerged, though it’s clear it was circulating in Europe before that alert. Nigeria initially stretched that timeline back even further, saying it found the variant in samples collected in October — but it later corrected that to say the cases were detected in travelers who arrived in the country in the past week.</p><p><blockquote>南非研究人员上周首次向世界卫生组织发出奥密克戎警报，但目前尚不清楚该变种首次出现的地点或时间，尽管很明显它在发出警报之前就在欧洲传播。尼日利亚最初将这一时间表进一步拉长，称在10月份收集的样本中发现了这种变异，但后来纠正说，这些病例是在过去一周抵达该国的旅行者中发现的。</blockquote></p><p> Regardless, the cases were the first reported in West Africa, while Saudi Arabia detected the first for a Gulf nation, a day after Brazil reported the first known one in Latin America.</p><p><blockquote>无论如何，这些病例是西非首例报告的，而沙特阿拉伯在海湾国家发现了首例病例，一天前巴西报告了拉丁美洲首例已知病例。</blockquote></p><p> Many countries around the world have barred travelers from southern Africa, and some have gone even further. Japan has banned foreign visitors and asked international airlines to stop taking new reservations for all flights arriving in the country until the end of December — among the most severe measures anywhere.</p><p><blockquote>世界上许多国家已经禁止来自南部非洲的游客，有些国家甚至更进一步。日本已禁止外国游客入境，并要求国际航空公司在12月底之前停止接受所有抵达该国航班的新预订，这是世界上最严厉的措施之一。</blockquote></p><p> The U.S. is working toward requiring that all air travelers to the country be tested for COVID-19 within a day before boarding their flight. Currently, those who are fully vaccinated may present a test taken within three days of boarding.</p><p><blockquote>美国正在努力要求所有飞往该国的航空旅客在登机前一天内接受新冠肺炎病毒检测。目前，那些完全接种疫苗的人可以在登机后三天内进行测试。</blockquote></p><p> Leaders have also continued to emphasize that the best way to contain the pandemic and future worrisome variants is to get vaccinated against COVID-19.</p><p><blockquote>领导人还继续强调，遏制疫情和未来令人担忧的变种的最佳方法是接种新冠肺炎疫苗。</blockquote></p><p> Meanwhile, officials from the top COVID-19 vaccine makers have said they’re also actively studying the omicron variant and assessing whether developing a tweaked shot is needed.</p><p><blockquote>与此同时，顶级COVID-19疫苗制造商的官员表示，他们也在积极研究奥密克戎变种，并评估是否需要开发一种经过调整的疫苗。</blockquote></p><p> Moderna CEO Stephane Bancel said this week that the company believes the omicron variant is highly infectious but it will take at least a \"week or two\" to determine how much the mutations have impacted the efficacy of current vaccines.</p><p><blockquote>Moderna首席执行官Stephane Bancel本周表示，该公司认为奥密克戎变种具有高度传染性，但至少需要“一两周”才能确定这些突变对当前疫苗功效的影响程度。</blockquote></p><p> \"Depending on how much it dropped, we might decide on the one hand to give a higher dose of the current vaccine around the world to protect people, maybe people at very high risk, the immunocompromised, and the elderly should need a fourth dose,\" Banceltold CNBC’s \"Squawk Box.\"</p><p><blockquote>“根据下降的程度，我们可能会决定一方面在世界各地注射更高剂量的当前疫苗，以保护人们，也许高危人群、免疫功能低下的人和老年人应该需要第四剂疫苗，”Bancel告诉CNBC的“Squawk Box”。</blockquote></p><p> Pfizer CEO Albert Bourla said the impact of omicron on the company’s COVID-19 vaccine is not yet known. But he added that Pfizer made its first \"DNA template\" on Friday, which is the start of the development process of a new vaccine in case it’s needed.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示，目前尚不清楚奥密克戎对该公司新冠疫苗的影响。但他补充说，辉瑞公司周五制作了第一个“DNA模板”，这是新疫苗开发过程的开始，以防需要。</blockquote></p><p> \"I don’t think that the result will be the vaccines don’t protect,\" Bourla told the outlet. \"I think the result could be, which we don’t know yet, the vaccines protect less.\"</p><p><blockquote>布尔拉告诉媒体：“我不认为结果是疫苗不能起到保护作用。”“我认为结果可能是，我们还不知道，疫苗的保护作用可能会减弱。”</blockquote></p><p> Any omicron-specific vaccine probably could not begin to be produced for another two or three months, Dr. Paul Burton, chief medical officer for Moderna, told the Associated Press on Monday. Burton added that in the interim, getting vaccinated and receiving a booster remains a \"very important initial line of defense.\"</p><p><blockquote>Moderna首席医疗官保罗·伯顿博士周一告诉美联社，任何针对奥密克戎的疫苗可能在未来两三个月内无法开始生产。伯顿补充说，在此期间，接种疫苗和接受加强剂仍然是“非常重要的第一道防线”。</blockquote></p><p></p>","source":"lsy1638497208227","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead says it expects remdesivir to remain effective against omicron variant<blockquote>吉利德表示预计瑞德西韦对奥密克戎变种仍有效</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead says it expects remdesivir to remain effective against omicron variant<blockquote>吉利德表示预计瑞德西韦对奥密克戎变种仍有效</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Fox13</strong><span class=\"h-time small\">2021-12-03 10:04</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>FOSTER CITY, Calif.</b>-Gilead Sciences, the maker of the COVID-19 treatment remdesivir, said it expects the drug to remain effective against the new COVID-19 omicron variant and will continue to conduct further laboratory testing to confirm.</p><p><blockquote><b>加利福尼亚州福斯特市。</b>——新冠治疗药物瑞德西韦的制造商吉利德科学表示，预计该药物对新冠奥密克戎变种仍有效，并将继续进行进一步的实验室检测以确认。</blockquote></p><p> Remdesivir, which is sold as Veklury, is an antiviral drug used to treat hospitalized COVID-19 patients 12 and up. It was the first COVID-19 treatment to receive FDA approval and recent data from a Phase 3 clinical trial found it to be 87% effective at reducing hospitalizations in high-risk patients who were diagnosed early.</p><p><blockquote>Remdesivir以Veklury出售，是一种抗病毒药物，用于治疗12岁及以上的住院COVID-19患者。这是第一个获得FDA批准的COVID-19治疗方法，最近一项3期临床试验的数据发现，它在减少早期诊断的高危患者住院方面有87%的有效性。</blockquote></p><p> In a statement,Gilead said Wednesday that it conducted a genetic analysis of more than 200 available sequences of the omicron variant, including those from South Africa, Asia and Europe, and found no additional \"prevalent mutations\" in the omicron variant as compared to previous strains.</p><p><blockquote>吉利德周三在一份声明中表示，它对奥密克戎变种的200多个可用序列进行了基因分析，包括来自南非、亚洲和欧洲的序列，与之前的菌株相比，奥密克戎变种没有发现额外的“流行突变”。</blockquote></p><p> \"This suggests that Veklury (remdesivir) will continue to be active against the Omicron variant and Gilead will conduct laboratory testing to confirm this analysis,\" the biopharmaceutical company said.</p><p><blockquote>这家生物制药公司表示：“这表明Veklury（remdesivir）将继续对奥密克戎病毒变种发挥作用，吉利德将进行实验室测试来证实这一分析。”</blockquote></p><p> The statement comes a day after Regener on said in its own statement that mutations present in the omicron variant \"indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody-conveyed immunity,\" including the company’s cocktail of two monoclonal antibodies.</p><p><blockquote>此前一天，Regener On在自己的声明中表示，奥密克戎变种中存在的突变“表明疫苗诱导和单克隆抗体传递的免疫的中和活性可能会降低”，包括该公司的两种单克隆抗体的混合物。</blockquote></p><p> Much remains unknown about omicron, including how contagious it is and whether it can evade vaccines and various treatments. But as reports of infections linked to the new strain have popped up in more parts of the globe, governments have rushed to impose restrictions in an effort to keep it out.</p><p><blockquote>关于奥密克戎病毒还有很多未知之处，包括它的传染性如何以及它是否可以逃避疫苗和各种治疗。但随着全球更多地区出现与新毒株相关的感染报告，各国政府纷纷采取限制措施，努力将其拒之门外。</blockquote></p><p> South African researchers first alerted the World Health Organization to omicron last week, but it is not known where or when the variant first emerged, though it’s clear it was circulating in Europe before that alert. Nigeria initially stretched that timeline back even further, saying it found the variant in samples collected in October — but it later corrected that to say the cases were detected in travelers who arrived in the country in the past week.</p><p><blockquote>南非研究人员上周首次向世界卫生组织发出奥密克戎警报，但目前尚不清楚该变种首次出现的地点或时间，尽管很明显它在发出警报之前就在欧洲传播。尼日利亚最初将这一时间表进一步拉长，称在10月份收集的样本中发现了这种变异，但后来纠正说，这些病例是在过去一周抵达该国的旅行者中发现的。</blockquote></p><p> Regardless, the cases were the first reported in West Africa, while Saudi Arabia detected the first for a Gulf nation, a day after Brazil reported the first known one in Latin America.</p><p><blockquote>无论如何，这些病例是西非首例报告的，而沙特阿拉伯在海湾国家发现了首例病例，一天前巴西报告了拉丁美洲首例已知病例。</blockquote></p><p> Many countries around the world have barred travelers from southern Africa, and some have gone even further. Japan has banned foreign visitors and asked international airlines to stop taking new reservations for all flights arriving in the country until the end of December — among the most severe measures anywhere.</p><p><blockquote>世界上许多国家已经禁止来自南部非洲的游客，有些国家甚至更进一步。日本已禁止外国游客入境，并要求国际航空公司在12月底之前停止接受所有抵达该国航班的新预订，这是世界上最严厉的措施之一。</blockquote></p><p> The U.S. is working toward requiring that all air travelers to the country be tested for COVID-19 within a day before boarding their flight. Currently, those who are fully vaccinated may present a test taken within three days of boarding.</p><p><blockquote>美国正在努力要求所有飞往该国的航空旅客在登机前一天内接受新冠肺炎病毒检测。目前，那些完全接种疫苗的人可以在登机后三天内进行测试。</blockquote></p><p> Leaders have also continued to emphasize that the best way to contain the pandemic and future worrisome variants is to get vaccinated against COVID-19.</p><p><blockquote>领导人还继续强调，遏制疫情和未来令人担忧的变种的最佳方法是接种新冠肺炎疫苗。</blockquote></p><p> Meanwhile, officials from the top COVID-19 vaccine makers have said they’re also actively studying the omicron variant and assessing whether developing a tweaked shot is needed.</p><p><blockquote>与此同时，顶级COVID-19疫苗制造商的官员表示，他们也在积极研究奥密克戎变种，并评估是否需要开发一种经过调整的疫苗。</blockquote></p><p> Moderna CEO Stephane Bancel said this week that the company believes the omicron variant is highly infectious but it will take at least a \"week or two\" to determine how much the mutations have impacted the efficacy of current vaccines.</p><p><blockquote>Moderna首席执行官Stephane Bancel本周表示，该公司认为奥密克戎变种具有高度传染性，但至少需要“一两周”才能确定这些突变对当前疫苗功效的影响程度。</blockquote></p><p> \"Depending on how much it dropped, we might decide on the one hand to give a higher dose of the current vaccine around the world to protect people, maybe people at very high risk, the immunocompromised, and the elderly should need a fourth dose,\" Banceltold CNBC’s \"Squawk Box.\"</p><p><blockquote>“根据下降的程度，我们可能会决定一方面在世界各地注射更高剂量的当前疫苗，以保护人们，也许高危人群、免疫功能低下的人和老年人应该需要第四剂疫苗，”Bancel告诉CNBC的“Squawk Box”。</blockquote></p><p> Pfizer CEO Albert Bourla said the impact of omicron on the company’s COVID-19 vaccine is not yet known. But he added that Pfizer made its first \"DNA template\" on Friday, which is the start of the development process of a new vaccine in case it’s needed.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示，目前尚不清楚奥密克戎对该公司新冠疫苗的影响。但他补充说，辉瑞公司周五制作了第一个“DNA模板”，这是新疫苗开发过程的开始，以防需要。</blockquote></p><p> \"I don’t think that the result will be the vaccines don’t protect,\" Bourla told the outlet. \"I think the result could be, which we don’t know yet, the vaccines protect less.\"</p><p><blockquote>布尔拉告诉媒体：“我不认为结果是疫苗不能起到保护作用。”“我认为结果可能是，我们还不知道，疫苗的保护作用可能会减弱。”</blockquote></p><p> Any omicron-specific vaccine probably could not begin to be produced for another two or three months, Dr. Paul Burton, chief medical officer for Moderna, told the Associated Press on Monday. Burton added that in the interim, getting vaccinated and receiving a booster remains a \"very important initial line of defense.\"</p><p><blockquote>Moderna首席医疗官保罗·伯顿博士周一告诉美联社，任何针对奥密克戎的疫苗可能在未来两三个月内无法开始生产。伯顿补充说，在此期间，接种疫苗和接受加强剂仍然是“非常重要的第一道防线”。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.q13fox.com/news/gilead-says-it-expects-remdesivir-to-remain-effective-against-omicron-variant\">Fox13</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"source_url":"https://www.q13fox.com/news/gilead-says-it-expects-remdesivir-to-remain-effective-against-omicron-variant","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103986245","content_text":"FOSTER CITY, Calif.-Gilead Sciences, the maker of the COVID-19 treatment remdesivir, said it expects the drug to remain effective against the new COVID-19 omicron variant and will continue to conduct further laboratory testing to confirm.\nRemdesivir, which is sold as Veklury, is an antiviral drug used to treat hospitalized COVID-19 patients 12 and up. It was the first COVID-19 treatment to receive FDA approval and recent data from a Phase 3 clinical trial found it to be 87% effective at reducing hospitalizations in high-risk patients who were diagnosed early.\nIn a statement,Gilead said Wednesday that it conducted a genetic analysis of more than 200 available sequences of the omicron variant, including those from South Africa, Asia and Europe, and found no additional \"prevalent mutations\" in the omicron variant as compared to previous strains.\n\"This suggests that Veklury (remdesivir) will continue to be active against the Omicron variant and Gilead will conduct laboratory testing to confirm this analysis,\" the biopharmaceutical company said.\nThe statement comes a day after Regener on said in its own statement that mutations present in the omicron variant \"indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody-conveyed immunity,\" including the company’s cocktail of two monoclonal antibodies.\nMuch remains unknown about omicron, including how contagious it is and whether it can evade vaccines and various treatments. But as reports of infections linked to the new strain have popped up in more parts of the globe, governments have rushed to impose restrictions in an effort to keep it out.\nSouth African researchers first alerted the World Health Organization to omicron last week, but it is not known where or when the variant first emerged, though it’s clear it was circulating in Europe before that alert. Nigeria initially stretched that timeline back even further, saying it found the variant in samples collected in October — but it later corrected that to say the cases were detected in travelers who arrived in the country in the past week.\nRegardless, the cases were the first reported in West Africa, while Saudi Arabia detected the first for a Gulf nation, a day after Brazil reported the first known one in Latin America.\nMany countries around the world have barred travelers from southern Africa, and some have gone even further. Japan has banned foreign visitors and asked international airlines to stop taking new reservations for all flights arriving in the country until the end of December — among the most severe measures anywhere.\nThe U.S. is working toward requiring that all air travelers to the country be tested for COVID-19 within a day before boarding their flight. Currently, those who are fully vaccinated may present a test taken within three days of boarding.\nLeaders have also continued to emphasize that the best way to contain the pandemic and future worrisome variants is to get vaccinated against COVID-19.\nMeanwhile, officials from the top COVID-19 vaccine makers have said they’re also actively studying the omicron variant and assessing whether developing a tweaked shot is needed.\nModerna CEO Stephane Bancel said this week that the company believes the omicron variant is highly infectious but it will take at least a \"week or two\" to determine how much the mutations have impacted the efficacy of current vaccines.\n\"Depending on how much it dropped, we might decide on the one hand to give a higher dose of the current vaccine around the world to protect people, maybe people at very high risk, the immunocompromised, and the elderly should need a fourth dose,\" Banceltold CNBC’s \"Squawk Box.\"\nPfizer CEO Albert Bourla said the impact of omicron on the company’s COVID-19 vaccine is not yet known. But he added that Pfizer made its first \"DNA template\" on Friday, which is the start of the development process of a new vaccine in case it’s needed.\n\"I don’t think that the result will be the vaccines don’t protect,\" Bourla told the outlet. \"I think the result could be, which we don’t know yet, the vaccines protect less.\"\nAny omicron-specific vaccine probably could not begin to be produced for another two or three months, Dr. Paul Burton, chief medical officer for Moderna, told the Associated Press on Monday. Burton added that in the interim, getting vaccinated and receiving a booster remains a \"very important initial line of defense.\"","news_type":1,"symbols_score_info":{"GILD":0.9}},"isVote":1,"tweetType":1,"viewCount":656,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/601186804"}
精彩评论